Mylan Inc. has announced that Mylan Pharmaceuticals Inc. has received final approval from the FDA for its Abbreviated New Drug Application (ANDA) for Granisetron Hydrochloride Tablets, 1 mg (base). Granisetron Hydrochloride Tablets are the generic version of Roche’s Kytril Tablets, which had U.S. sales of approximately $89 million for the 12 months ending Sept. 30, 2007, according to IMS Health.
Related Articles Read More >
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
Eicos Sciences’ FDA-approved Aurlumyn promises to drastically reduce frostbite amputations
